Close Menu

Accelerate Diagnostics

Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.

The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.

Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.

The firm missed Wall Street expectations due in part to an elongated sales cycle and the timing of commercial go-lives.

Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.

Companies in the AMR space have met resistance from investors and clinicians as a result of conflicting hospital priorities and perceived technology shortcomings.

New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.

The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.

The appointment of a former Roche executive as the firm's new COO is viewed as a significant event for a firm still in the early stages of driving adoption of its Pheno system.

The updated test now includes additional susceptibility testing and clinical interpretive breakpoints that are compliant with 2019 European guidance.

Pages